Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

This publication has 29 references indexed in Scilit:

• Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents
  Published by Elsevier ,1999
• Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro
  Proceedings of the National Academy of Sciences, 1999
• MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
  Journal of Urology, 1998
• Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
  Proceedings of the National Academy of Sciences, 1998
• Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.
  JNCI Journal of the National Cancer Institute, 1998
• Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
  British Journal of Cancer, 1998
• Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
  Science, 1998
• Peptide growth factors and prostate cancer: new models, new opportunities.
  Cancer and Metastasis Reviews, 1998
• Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
  British Journal of Cancer, 1997
• A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
  New England Journal of Medicine, 1989